Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.780
-0.210 (-4.21%)
At close: Sep 11, 2026, 4:00 PM EDT
4.740
-0.040 (-0.83%)
After-hours: Sep 11, 2026, 7:39 PM EDT
Aquestive Therapeutics Employees
Aquestive Therapeutics had 147 employees as of December 31, 2025. The number of employees increased by 5 or 3.52% compared to the previous year.
Employees
147
Change (1Y)
5
Growth (1Y)
3.52%
Revenue / Employee
$367,939
Profits / Employee
-$532,156
Market Cap
599.95M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 147 | 5 | 3.52% |
| Dec 31, 2024 | 142 | 7 | 5.19% |
| Dec 31, 2023 | 135 | 5 | 3.85% |
| Dec 31, 2022 | 130 | -27 | -17.20% |
| Dec 31, 2021 | 157 | -30 | -16.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,461 |
| Tilray Brands | 3,595 |
| Canopy Growth | 1,128 |
| Pacira BioSciences | 829 |
| Kamada | 462 |
| Glass House Brands | 426 |
| Collegium Pharmaceutical | 423 |
| Evolus | 353 |
AQST News
- 3 days ago - Aquestive Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 11 days ago - Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 4 weeks ago - Aquestive Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Aquestive Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Aquestive Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Aquestive Therapeutics Slides: Q2 2026 - Filings
- 4 weeks ago - Aquestive Therapeutics reports Q2 EPS (18c), consensus (12c) - TheFly
- 4 weeks ago - Aquestive Therapeutics backs FY26 revenue view $46M-$50M, consensus $50.51M - TheFly